{"url_path":"/sec/slbt/10-k/2026/item-6","section_key":"item-6","section_title":"Item 6 DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES**","topic":"sec","document":{"doc_type":"20-F","doc_date":"2026-06-18","source_url":"https://www.sec.gov/Archives/edgar/data/2070534/0001213900-26-070158-index.html","accession_number":"0001213900-26-070158","cik":"0002070534","ticker":"SLBT","issuer_name":"SL Science Holding Ltd","edgar_url":"https://www.sec.gov/Archives/edgar/data/2070534/0001213900-26-070158-index.html","primary_entity_key":"0002070534","primary_entity_name":"SL Science Holding Ltd"},"word_count":780,"has_tables":true,"body_markdown":"**ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES**\n\n** **\n\n**A.**\n**Directors and Senior Management**\n\nThe directors and executive\nofficers upon the consummation of the Business Combination are set forth in the Form F-4, in the section titled “Management of PubCo\nFollowing the Business Combination,” which is incorporated herein by reference.\n\nThe information of the two\nadditional independent directors of the Company taking office upon the consummation of the Business Combination is set forth below.\n\n**Joseph Levinson.** Mr.\nLevinson has over 25 years of experience managing cross-border issues for U.S.-listed foreign companies, as well as experience in accounting.\nFrom January 2025 to July 2025, Mr. Levinson served as an independent director of Robo.ai Inc., formerly known as NWTN Inc. (Nasdaq: AIIO),\na company in the electric vehicle industry. From May 2020 to September 2021, he served as an independent director of China Liberal Education\nHoldings Ltd. (Nasdaq: CLEU), an educational service provider. Mr. Levinson worked for firms such as KPMG and Deloitte & Touche early\nin his career. Mr. Levinson received a bachelor’s degree from the University at Buffalo with a double major in finance and accounting,\ngraduating summa cum laude, and he holds a United States Certified Public Accountant license for more than 25 years. He is qualified to\nserve as a director due to his accounting and public company experience.\n\n**Qian (Hebe) Xu.**Ms.\nXu has served as HSPT’s independent director since November 2024. She has more than 15 years’ experience in\nthe financial markets as an investment banker, specializing in US-China cross border transactions. Ms. Xu also serves as an Independent\nDirector of Hongli Group Inc. (Nasdaq: HLP), a position held since 2023. Since October 2018, Ms. Xu has served as the founder\nof HB International Consulting LLC, a firm providing business consulting and financial advisory services. From November 2008 to October 2018,\nMs. Xu worked at TriPoint Global Equities LLC, an investment banking firm, as an Analyst (November 2008 to April 2013), as Vice\nPresident of investment banking (from April 2013 to May 2017) and the Senior Vice President (from May 2017 to October 2018),\nleading effort of the US-China cross border investment, mergers & acquisitions, and initial public offerings. Ms. Xu received\nher Bachelor’s degree in Telecommunication Engineering from Sun Yat-Sen (Zhongshan) University in 2004 and a Master’s\ndegree in Economics from New York University in 2009.\n\nNeither Joseph Levinson nor\nQian (Hebe) Xu will serve as a member of PubCo’s board committees.\n\nAccordingly, the directors and executive officers of PubCo following\nthe Business Combination are set forth as follows:\n\n**Name**\n\n**Age**\n\n**Position**\n\nWilliam Wang Ching-Dong\n\n55\n\nChief Executive Officer, Director, and Chairman of Board\n\nRay Leung\n\n45\n\nChief Financial Officer\n\nJohnson Lau\n\n52\n\nVice President of Finance\n\nEthan Shen, Ph.D.\n\n49\n\nChief Technology Officer and Director\n\nKwo-Liang Chen\n\n65\n\nIndependent Director\n\nMingche Liu, M.D., Ph.D.\n\n53\n\nIndependent Director\n\nJohn C. General\n\n63\n\nIndependent Director\n\nJoseph Levinson\n\n50\n\nIndependent Director\n\nQian (Hebe) Xu\n\n44\n\nIndependent Director\n\n26\n\n** **\n\n**B.**\n**Compensation**\n\nInformation pertaining to\nthe compensation of the Company’s directors and executive officers is set forth in the Form F-4 in the sections entitled “Management\nof SL Bio — Executive Compensation” and “Management of PubCo Following the Business Combination — Compensation\nof Directors and Officers,” which are incorporated herein by reference.\n\n****\n\n**C.**\n**Board Practices**\n\nInformation pertaining to\nthe Company’s board practices is set forth in the Form F-4, in the section titled “Management of PubCo Following the Business\nCombination,” which is incorporated herein by reference.\n\n** **\n\n**D.**\n**Employees**\n\nAs of December 31, 2025, we\nemployed 20 full-time employees. We have never had a work stoppage, and none of our employees are represented by a labor organization\nor under any collective bargaining arrangements. We consider our employee relations to be good. Certain employees are subject to contractual\nagreements that specify requirements on confidentiality and restrictions on working for competitors, as well as other standard matters.\n\nAdditionally, we are strategically\nexpanding our workforce to strengthen our capabilities in the biomedical field. As part of this initiative, we plan to hire an additional\nsenior scientist as Chief Medical Officer prior to the Phase I clinic trails of the product candidates in 2026. These highly skilled professionals\nwill focus on advancing our research and development efforts, enabling us to drive innovation and enhance operational excellence. By investing\nin a top-tier team and cutting-edge facilities, we are positioning SL Science to accelerate groundbreaking advancements in the biomedical\nsector. This expansion underscores our commitment to delivering impactful solutions that address critical healthcare challenges and improve\npatient outcomes globally.\n\n** **\n\n**E.**\n**Share Ownership**\n\nOwnership of the Ordinary\nShares by its directors and executive officers upon the consummation of the Business Combination is set forth in Item 7.A of this Report."}